Search results
Pharma Stock Roundup: BAYRY's Q1 Earnings, JNJ's New Buyout, Pipeline Updates
Zacks via Yahoo Finance· 5 days agoData from a pre-planned analysis of the KeyVibe-010 study showed that the primary...
Johnson & Johnson to acquire Proteologix for $850 million
New Hampshire Union Leader· 6 days agoJohnson & Johnson said it would acquire Proteologix for $850 million as it looks to gain access to...
Do LED Skin-Care Devices Even Work?
New York Magazine· 15 hours agoLight therapy via at-home LED (light-emitting diodes) devices is trending in skin care right now, but it’s not just a fad. According to Dr. Jared Jagdeo,...
Johnson & Johnson to acquire Proteologix for $850 million
Reuters via Yahoo Finance· 6 days agoProteologix's antibody PX128 is ready to enter early-stage development for moderate to severe atopic...
Johnson & Johnson to acquire Proteologix for $850 million By Reuters
Investing.com· 6 days agoProteologix's antibody PX128 is ready to enter early-stage development for moderate to severe atopic...
Stress can be "the triggering factor" for skin problems. Dermatologists share their advice. - WDEF
WDEF Chattanooga· 15 hours agoDermatologist Dr. Afton Cobb says she sees patients all the time who notice “the triggering factor...
Stress can be "the triggering factor" for skin problems. Dermatologists share their advice.
CBS News· 22 hours agoThere are many ways mental health can impact our physical health — but did you know stress can even...
Pharma Stock Roundup: BAYRY's Q1 Earnings, JNJ's New Buyout, Pipeline Updates
Zacks· 5 days agoBayer (BAYRY) releases Q1 results. J&J (JNJ) set to acquire private biotech, Proteologix, which will add atopic dermatitis candidates.
Why Is My Scalp Flaky? Exploring The Causes Of Dandruff And How It’s Treated
IFLScience· 4 days agoAccording to the American Academy of Dermatology, dandruff itself may be considered a mild form of a...
Johnson & Johnson to Acquire Proteologix, Inc. to Lead in Atopic Dermatitis Treatment
Morningstar· 6 days agoProteologix’s portfolio includes PX128, a bispecific antibody targeting IL-13 plus TSLP, which is ready to enter phase 1 development for moderate to severe atopic dermatitis ...